China Chemical Pharmaceutical Industry Report, 2013-2016
  • June 2014
  • Hard Copy
  • USD $2,700
  • Pages:131
  • Single User License
    (PDF Unprintable)       
  • USD $2,500
  • Code: ZYM055
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,900
  • Hard Copy + Single User License
  • USD $2,900

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than that of the API over the same period. In 2013, China chemical drug preparation industry and?China API industry recorded revenue of RMB 573.1 billion and RMB 382 billion, with gross margin of 35%-40% and 20%, respectively.

China is a big producer of chemical APIs, capable of producing about 1,600 varieties of APIs. China ranks first worldwide in output of several bulk APIs including penicillins, vitamins and antipyretic analgesics, and holds a significant share of the featured APIs like statins, prils, sartans in the world. China produced 2.709 million tons of chemical APIs in 2013.

Although China is the world's leading chemical APIs supply region, the concentration of China chemical APIs industry is rather low due to numerous categories of APIs and limited overall strength of domestic enterprises, which occupy an important place only in single or a few categories of pharmaceuticals market. In addition, under the pressure of both environmental protection and industrial upgrading, many large APIs companies in the country are transforming into drug preparation companies through means such as R&D and acquisitions.

North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd. are major suppliers of antibiotic and VC APIs in China, with supply of VS reaching around 20,000 tons each. In 2013, the two companies’ total revenue from APIs and their revenue from drug preparation business reached RMB 5.695 billion and RMB 3.871 billion, respectively.

Zhejiang Medicine Co., Ltd. and Zhejiang NHU Co., Ltd. are the leading manufacturers of VE products around the globe, with raw materials (vital ingredients for the production of VE are limited raw materials: isophytol and trimethylhydroquinone) for VE being produced by themselves. However, the two companies’ development is constrained due to a weak global demand for VE, of which Zhejiang Medicine reported revenue of RMB 4.915 billion from pharmaceutical business (APIs+ preparation), down 6.3% year on year.

Zhejiang Hisun Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. are the key suppliers of featured APIs in China, of which the former specializes in antineoplastic and cardiovascular products, and the latter, which obtains three certificates from EDQM in 2013, is a major global supplier of prils and sartans APIs. In 2013, the two companies’ total revenues from APIs and drug preparation business were RMB 3.226 billion and RMB 2.272 billion, rising by 19.5% and 14.7% from the previous year, respectively.

Zhejiang Xianju Pharmaceutical Co., Ltd. and Tianjin Tianyao Pharmaceuticals Co., Ltd. are the leading suppliers of hormone APIs, of which the former has been aggressively expanding into downstream drug preparation business. In the context of stricter environmental standards and rising costs of raw materials, developing the downstream will undoubtedly ensure competitiveness of the company. In 2013, Xianju Pharmaceutical posted total revenue of RMB 2.233 billion from APIs and preparation business, up 16.2% against the prior year. Also in 2013, the company acquired three EDQM certificates for its APIs.

化学制药 英文_副本.jpg

China Chemical Pharmaceutical Industry Report, 2013-2016 highlights the following:
20120114.gifDevelopment status quo, supply and demand, regional structure and trend of global chemical pharmaceutical industry;
20120114.gifDevelopment status quo, competitive landscape, import and export and forecast of China chemical pharmaceutical industry;
20120114.gifDevelopment status quo, competitive landscape and import and export of China chemical pharmaceutical segments, including vitamins, antibiotics, antipyretic analgesics, antineoplastics and cardiovascular and cerebrovascular;
20120114.gifOperation and prospects of 20 Chinese chemical APIs and preparation companies.

1. Overview of Chemical Pharmaceutical Industry
1.1 Definition and Classification
1.2 Industry Chain

2. Development of Global Chemical Pharmaceutical Industry
2.1 Status Quo
2.2 Supply and Demand
2.2.1 Product Mix
2.2.1 Regional Structure
2.3 Major Countries and Regions
2.3.1 North America
2.3.2 Europe
2.3.3 Emerging Countries
2.4 Development Trends
2.4.1 Proprietary Drugs in Trouble, Generic Drugs with Great Potential
2.4.2 Emerging Countries Being Growth Engines 

3. Development of China Chemical Pharmaceutical Industry
3.1 Status Quo
3.1.1 Overall Conditions
3.1.2 Improvement in Pharmaceutical Innovation Capability 
3.1.3 Active Merger and Reorganization of Pharmaceutical Companies
3.2 Operating Capability
3.3 Import and Export
3.3.1 Chemical Preparations
3.3.2 Chemical APIs
3.4 Competitive Landscape

4. China Chemical Pharmaceutical Market Segments
4.1 Vitamins 
4.1.1 Status Quo
4.1.2 Competitive Landscape
4.1.3 Import and Export
4.2 Antibiotics
4.2.1 Status Quo
4.2.2 Competitive Landscape
4.2.3 Import and Export
4.3 Antipyretic Analgesics
4.3.1 Status Quo
4.3.2 Competitive Landscape
4.3.3 Import and Export
4.4 Hormones
4.4.1 Status Quo
4.4.2 Competitive Landscape
4.4.3 Import and Export
4.5 Anti-tumor
4.5.1 Status Quo
4.5.2 Competitive Landscape
4.6 Cardiovascular and Cerebrovascular
4.6.1 Status Quo
4.6.2 Competitive Landscape

5. Key Chinese Chemical APIs Manufacturers
5.1 Northeast Pharmaceutical Group Co., Ltd.
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 R&D
5.1.5 Prospects
5.2 North China Pharmaceutical Co., Ltd.
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 R&D
5.2.5 Prospects
5.3 Zhejiang Medicine Co., Ltd.
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Investment and R&D
5.3.5 Forecast
5.4 Zhejiang Hisun Pharmaceutical Co., Ltd.
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 R&D
5.5.5 Prospects
5.5 Zhejiang NHU Co., Ltd.
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 R&D
5.5.5 Prospects
5.6 Shandong Xinhua Pharmaceutical Company Limited
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 R&D
5.6.5 Prospects
5.7 Shenzhen Hepalink Pharmaceutical Co., Ltd.
5.7.1 Profile
5.7.2 Operation
5.7.2 Revenue Structure
5.7.4 R&D
5.7.5 Prospects
5.8 Zhejiang Xianju Pharmaceutical Co., Ltd.
5.8.1 Profile
5.8.2 Operation
5.8.3 Revenue Structure
5.8.4 R&D
5.8.5 Prospects
5.9 Zhejiang Huahai Pharmaceutical Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.9.3 Revenue Structure
5.9.4 R&D
5.9.5 Forecast
5.10 Tianjin Tianyao Pharmaceuticals Co., Ltd.
5.10.1 Profile
5.10.2 Operation
5.10.3 Revenue Structure
5.10.3 Investment and R&D
5.10.4 Prospects

6. Key Chinese Chemical Preparation Manufacturers
6.1 China Resources Double-Crane Pharmaceutical Co., Ltd.
6.1.1 Profile
6.1.2 Operation
6.1.3 Revenue Structure
6.1.4 Investment and R&D
6.1.5 Prospects
6.2 Jiangsu Hengrui Medicine Co., Ltd.
6.2.1 Profile
6.2.2 Operation
6.2.3 Revenue Structure
6.2.4 R&D and Investment
6.2.5 Prospects
6.3 Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd.
6.3.1 Profile
6.3.2 Operation
6.3.3 Revenue Structure
6.3.4 R&D and Investment
6.4 Xizang Haisco Pharmaceutical Group Co., Ltd.
6.4.1 Profile
6.4.2 Operation
6.4.3 Revenue Structure
6.4.4 Investment and R&D
6.4.5 Prospects
6.5 Livzon Pharmaceutical Group Inc.
6.5.1 Profile
6.5.2 Operation
6.5.3 Revenue Structure
6.5.4 Prospects
6.6 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
6.6.1 Profile
6.6.2 Operation
6.6.3 Revenue Structure
6.6.4 R&D and Investment
6.6.5 Prospects
6.7 Jiangsu Nhwa Pharmaceutical Co., Ltd.
6.7.1 Profile
6.7.2 Operation
6.7.3 Revenue Structure
6.7.4 R&D
6.7.5 Prospects
6.8 Hainan Haiyao Co., Ltd.
6.8.1 Profile
6.8.2 Operation
6.8.3 Revenue Structure
6.8.4 R&D
6.8.5 Prospects
6.9 Huaren Pharmaceutical Co., Ltd.
6.9.1 Profile
6.9.2 Operation
6.9.3 Revenue Structure
6.9.4 Investment and R&D
6.9.5 Prospects
6.10 Humanwell Healthcare (Group) Co., Ltd.
6.10.1 Profile
6.10.2 Operation
6.10.3 Revenue Structure
6.10.4 Investment and R&D
6.10.5 Prospects

7. Conclusion and Forecast
7.1 Overall 
7.1.1 Market Size Forecast
7.1.2 Profit Forecast
7.2 Companies
Classification of Sub-sectors of China Chemical Pharmaceutical Industry
Profit Distribution of Chemical Pharmaceutical Industry
Size and YoY Growth Rate of Global Pharmaceuticals Market, 2003-2013
M&A Transaction Value in Global Pharmaceutical Industry, 2013
Global Top10 Mergers and Acquisitions in Pharmaceutical Industry, 2013
Number of New Drugs Approved by FDA, 2010-2013
New Drugs Approved by FDA and Sales, 2013
Blockbuster Drugs and Sales of 15 Large Global Pharmaceutical Companies, 2013
Sales Proportion of Global Generic Drugs, 2008-2013
Regional Distribution of Global Pharmaceutical Industry 
Size and YoY Growth Rate of Global Pharmaceuticals Market by Country and Region, 2012
Global Pharmaceutical Market Scale Ranking, 2003-2013 
Proportion of Spending on Health Care to GDP in the U.S. and Canada, 1995-2012
Pharmaceuticals Sales in the United States, 2010-2012
Proportion of Spending on Health Care to GDP in Britain and France, 1995-2012
Pharmaceuticals Sales in Western Europe, 2010-2012
Pharmaceuticals Sales in Emerging Countries, 2010-2012
Contributions of Emerging Countries to Global Pharmaceuticals Sales Growth, 2010-2012
Real GDP Growth Rates of China, U.S., Britain and India, 2000-2012
Total Output Value and % of GDP of China Chemical Pharmaceutical Industry, 2010-2013
Comparison of Revenue from China Chemical APIs and Preparation Industries, 2010-2013
Output of Chemical APIs in China, 2007-2013
Pharmaceuticals Approved for Marketing in China, 2013
Revenue and Profit of China Chemical Preparation Industry, 2010-2013
Revenue and Profit of China Chemical APIs Industry, 2010-2013
Gross Margin of China Chemical Preparation and Chemical APIs Industry, 2010-2013
Import and Export Value of Chemical APIs in China, 2010-2013
Export Value and YoY Growth Rate of Featured APIs in China, 2010-2013
Regional Distribution of China’s Chemical API Export by Value, 2013
Chemical Pharmaceuticals Purchase Amount Breakdown of China’s Hospitals by Disease Pattern, 2012
Output and % of Vitamin in Export Volume in China, 2010-2013
Major Vitamin C Companies and Their Output in China, 2012
Major Vitamin E Companies and Their Output in China, 2012
Export Volume and Value and Average Price of China’s Vitamins, 2009-2013
Proportion of Export Volume of China’s Vitamins by Product, 2008-2013
Export Destinations of China’s Vitamins, 2013
Import Volume and Value and Average Price of Vitamins in China, 2010-2013
Proportion of Import Volume of Vitamins in China by Product, 2008-2013
Sources of Imported Vitamins in China, 2013
Output of Main Antibiotic APIs in China, 2012
Output of Main Antibiotic Preparations in China, 2012
Manufacturers and Output of Main Antibiotic APIs in China, 2012
Import Volume and Value of Antibiotics in China, 2008-2013
Export Volume and Value of Antibiotics in China, 2008-2013
Output and Export Volume of Antipyretic Analgesics APIs in China, 2012
Export Volume of Antipyretic Analgesics APIs in China, 2012
Export Structure of Antipyretic Analgesics APIs in China by Volume, 2012
Hormone Drugs Output in China, 2010-2012
Output of Main Hormone APIs in China, 2012
Export Volume and Value of Hormone Products in China, 2013
China Antineoplastic Agent Market Size, 2006-2013
Purchase Amount and Proportion of Main Antineoplastic and Immunoregulatory Drugs in Typical Hospitals of 22 Cities in China, 2012
Purchase Amount and Proportion of Main Cardiovascular System Drugs in Typical Hospitals of 22 Cities in China, 2012
Revenue and Net Income of Northeast Pharmaceutical, 2010-2013
Output and Export Volume of VC Series Products of Northeast Pharmaceutical, 2011-2012
Operating Revenue of Northeast Pharmaceutical by Product, 2010-2013
Operating Revenue of Northeast Pharmaceutical by Region, 2010-2013
Revenue and Net Income of Northeast Pharmaceutical, 2013-2016E
Output and Export Volume of Some APIs of North China Pharmaceutical, 2012
Revenue and Net Income of North China Pharmaceutical, 2009-2013
Operating Revenue of North China Pharmaceutical by Product, 2009-2013
Operating Revenue of North China Pharmaceutical by Region, 2009-2013
R&D Costs and % of Revenue of North China Pharmaceutical, 2011-2013
Revenue and Net Income of North China Pharmaceutical, 2013-2016E
Output and Export Volume of Some APIs of Zhejiang Medicine, 2012
Revenue and Net Income of Zhejiang Medicine, 2009-2013
Revenue of Zhejiang Medicine by Product, 2009-2013
Revenue of Zhejiang Medicine by Region, 2009-2013
R&D Costs and % of Revenue of Zhejiang Medicine, 2011-2013
Revenue and Net Income of Zhejiang Medicine, 2013-2016E
Revenue and Net Income of Zhejiang Hisun Pharmaceutical, 2010-2013
Operating Revenue of Zhejiang Hisun Pharmaceutical by Product, 2009-2013
Operating Revenue of Zhejiang Hisun Pharmaceutical by Region, 2009-2013
R&D Costs and % of Revenue of Zhejiang Hisun Pharmaceutical, 2010-2013
Revenue and Net Income of Zhejiang Hisun Pharmaceutical, 2013-2016E
Revenue and Net Income of Zhejiang NHU Co., Ltd., 2009-2013
Operating Revenue of Zhejiang NHU Co., Ltd. by Product, 2010-2013
Operating Revenue of Zhejiang NHU Co., Ltd. by Region, 2010-2013
R&D Costs and % of Revenue of Zhejiang NHU Co., 2010-2014
Revenue and Net Income of Zhejiang NHU Co., 2013-2016E
Revenue and Net Income of Shandong Xinhua Pharmaceutical, 2009-2013
Operating Revenue of Shandong Xinhua Pharmaceutical by Product, 2010-2013
Main Products and % of Revenue of Shandong Xinhua Pharmaceutical, 2013
Revenue and Net Income of Shandong Xinhua Pharmaceutical, 2013-2016E
Revenue and Net Income of Shenzhen Hepalink Pharmaceutical, 2009-2013
Operating Revenue of Shenzhen Hepalink Pharmaceutical by Product, 2009-2013
Operating Revenue of Shenzhen Hepalink Pharmaceutical by Region, 2009-2013
R&D Costs and % of Revenue of Shenzhen Hepalink Pharmaceutical, 2009-2013
Revenue and Net Income of Zhejiang Xianju Pharmaceutical, 2009-2013
Operating Revenue of Zhejiang Xianju Pharmaceutical by Product, 2009-2013
Operating Revenue of Zhejiang Xianju Pharmaceutical by Region, 2009-2013
R&D Costs and % of Revenue of Zhejiang Xianju Pharmaceutical, 2010-2013
Revenue and Net Income of Zhejiang Xianju Pharmaceutical, 2013-2016E
Revenue and Net Income of Zhejiang Huahai Pharmaceutical, 2009-2013
Revenue of Zhejiang Huahai Pharmaceutical by Product, 2009-2013
Revenue of Zhejiang Huahai Pharmaceutical by Region, 2010-2013
R&D Costs and % of Revenue of Zhejiang Huahai Pharmaceutical, 2011-2013
Revenue and Net Income of Zhejiang Huahai Pharmaceutical, 2013-2016E
Revenue and Net Income of Tianjin Tianyao Pharmaceuticals, 2010-2013
Revenue of Tianjin Tianyao Pharmaceuticals by Product, 2010-2013
Revenue of Tianjin Tianyao Pharmaceuticals by Region, 2010-2013
R&D Costs and % of Revenue of Tianjin Tianyao Pharmaceuticals, 2013
Investment Projects of Tianjin Tianyao Pharmaceuticals, 2013 
Revenue and Net Income of Tianjin Tianyao Pharmaceuticals, 2013-2016E
Revenue and Net Income of China Resources Double-Crane Pharmaceutical, 2010-2013
Revenue Structure of China Resources Double-Crane Pharmaceutical by Sector, 2010-2013
Gross Margin of China Resources Double-Crane Pharmaceutical by Product, 2013
Revenue of China Resources Double-Crane Pharmaceutical by Region, 2010-2013
Construction Projects Invested by China Resources Double-Crane Pharmaceutical, 2013
R&D Expenditure Structure of China Resources Double-Crane Pharmaceutical, 2013
Revenue and Net Income of China Resources Double-Crane Pharmaceutical, 2013-2016E
Revenue and Net Income of Jiangsu Hengrui Medicine, 2010-2013
Operating Revenue of Jiangsu Hengrui Medicine by Product, 2010-2013
R&D Expenditure of Jiangsu Hengrui Medicine, 2013
Progress of Investment Projects of Jiangsu Hengrui Medicine as of 2013
Revenue and Net Income of Jiangsu Hengrui Medicine, 2013-2016E
Revenue and Net Income of Harbin Pharm. Group Sanjing Pharmaceutical Shareholding, 2010-2013
Operating Revenue of Harbin Pharm. Group Sanjing Pharmaceutical Shareholding by Product, 2010-2013
R&D Expenditure of Harbin Pharm. Group Sanjing Pharmaceutical Shareholding, 2013 
Revenue and Net Income of Xizang Haisco Pharmaceutical, 2010-2013
Revenue and Gross Margin of Xizang Haisco Pharmaceutical by Product, 2013
Revenue of Xizang Haisco Pharmaceutical by Region, 2010-2013
Investment Projects of Xizang Haisco Pharmaceutical, 2013
R&D Expenditure of Xizang Haisco Pharmaceutical, 2010-2013
Revenue and Net Income of Xizang Haisco Pharmaceutical, 2013-2016E
Revenue and Net Income of Livzon Pharmaceutical Group, 2008-2013
Operating Revenue of Livzon Pharmaceutical Group by Product, 2008-2013
Operating Revenue of Livzon Pharmaceutical Group by Region, 2008-2013
Revenue and Net Income of Livzon Pharmaceutical Group, 2013-2016E
Revenue and Net Income of Shanghai Fosun Pharmaceutical, 2008-2013
Operating Revenue of Shanghai Fosun Pharmaceutical by Product, 2008-2013
Operating Revenue of Shanghai Fosun Pharmaceutical by Region, 2008-2013
R&D Costs and % of Revenue of Shanghai Fosun Pharmaceutical, 2008-2013
Revenue and Net Income of Shanghai Fosun Pharmaceutical, 2013-2016E
Revenue and Net Income of Jiangsu Nhwa Pharmaceutical, 2009-2013
Revenue of Jiangsu Nhwa Pharmaceutical by Product, 2009-2013
R&D Costs and % of Revenue of Jiangsu Nhwa Pharmaceutical, 2010-2013
Revenue and Net Income of Jiangsu Nhwa Pharmaceutical, 2013-2016E
Revenue and Net Income of Hainan Haiyao, 2009-2013
Operating Revenue of Hainan Haiyao by Product, 2009-2013
R&D Costs and % of Revenue of Hainan Haiyao, 2011-2013
Revenue and Net Income of Hainan Haiyao, 2013-2016E
Revenue and Net Income of Huaren Pharmaceutical, 2010-2013
Revenue of Huaren Pharmaceutical by Product, 2010-2013
Gross Margin of Huaren Pharmaceutical by Product, 2010-2013
Revenue of Huaren Pharmaceutical by Region, 2013
Investment Projects of Huaren Pharmaceutical, 2013
Mergers and Acquisitions Conducted by Huaren Pharmaceutical, 2013
R&D Expenditure of Huaren Pharmaceutical, 2011-2013
Revenue and Net Income of Huaren Pharmaceutical, 2013-2016E
Revenue and Net Income of Humanwell Healthcare, 2010-2013
Revenue and Gross Margin of Humanwell Healthcare by Product, 2013
Revenue of Humanwell Healthcare by Region, 2010-2013
Project Investment of Humanwell Healthcare, 2013
Equity Investment of Humanwell Healthcare, 2013
Revenue and Net Income of Humanwell Healthcare, 2013-2016E
Number of People Aged 65 and Over and Percentage of Total Population, 2004-2013
Revenue of Chemical Preparations and Chemical APIs in China, 2010-2016E
Gross Margin of Chemical Preparations and Chemical APIs in China, 2010-2016E
Revenue and Main Products of Key Chemical APIs Companies in China, 2013
Revenue of Key Chemical Preparations Companies in China, 2013

China Contract Research Organization (CRO) Industry Report, 2020-2026

The contract research organization (CRO) industry has been galloping amid the global pharmaceutical market steadily in head way, the vibrant financing in the medical and health sector, and the prolife...

China Human Vaccine Industry Report, 2020-2026

In China, the lot release for human vaccines plunged by 17.7% in 2018 when the production record fraud of rabies vaccines for human use, freeze-dried by Changsheng Bio-Technology was exposed. The impa...

China Pharmaceutical Distribution Industry Report, 2019-2026

The Chinese pharmaceutical distribution market has been expanding steadily over the recent years, being valued at RMB2,330.3 billion in 2019 with a year-on-year increase of 8.9%, of which the pharmace...

China Pharmaceutical Distribution Industry Report, 2019-2025

China’s pharmaceutical distribution industry has sustained steady growth over the years. In 2018, the market was worth RMB2,194.5 billion, a 9.6% rise from RMB2,001.6 billion (up by 8.4% YoY) in 2017,...

China Pharmaceutical Packaging Industry Report, 2019-2025

Being incentivized by the burgeoning pharmaceuticals industry, Chinese pharmaceutical packaging market size sustained growth rates of around 10% in recent years, and outstripped RMB100 billion in 2018...

China Blood Product Industry Report, 2018-2022

The blood product industry in China develops under stimulation of industry policies and downstream demand. The country recorded total lot release volume of 64.11 million bottles of blood products in 2...

China Pharmaceutical Distribution Industry Report, 2017-2021

The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit...

China Blood Product Industry Report, 2017-2021

China’s blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 201...

China Pharmaceutical Packaging Industry Report, 2016-2021

Under the impetus of the fast-growing downstream pharmaceutical industry, Chinese pharmaceutical packaging market size increased year by year at the CAGR of 11.2% during 2010-2016. From 2017 to 2021, ...

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Ch...

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号